Abbott Laboratories
NYSE:ABTMedical - Devices
-$0.51 today
- Market cap
- $180.95B
- Beta
- 0.62
- P/E (TTM)
- 24.5
- EPS (TTM)
- $3.59
- Dividend yield
- 2.77%
Volume 7.02M
Average 13.17M
ABT Operating Margin
Operating income as a percentage of revenue, showing the profitability of core operations.
Abbott LaboratoriesNYSE: ABT
Operating Margin · Q3 FY2026 · quarter ended Sep 2026
Operating margin narrows to 11.3%
Operating margin was 11.3% in Q3 FY2026, down 6.8 pp from a year earlier. On a trailing-twelve-month basis it was 15.2%, down 2.5 pp year over year. Over 3 fiscal years it narrowed by 1.0 pp.
Context
- Operating margin widened in 2 of the last 3 fiscal years.
What to watch
Whether operating margin reaches the consensus estimate from 20 analysts of 23.4% for the fiscal year ending Dec 2026, up from 18.2% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- 11.3%-2.8 pp QoQ
- Last fiscal yearDec 2025
- 18.2%+1.9 pp YoY
- LTMSep 2026
- 15.2%-2.5 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -6.8 pp | +7.4 pp | +14.1 pp |
| 1 year | +1.9 pp | +5.2 pp | +3.3 pp |
| 3 years | -1.0 pp | +5.7 pp | +6.7 pp |
| 5 years | +7.1 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 18.2%
- Year-over-year change
- +1.9pp
| Period | Period end | Operating Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 18.2% | +1.9pp |
| FY2024 | 2024-12-31 | 16.3% | +0.2pp |
| FY2023 | 2023-12-31 | 16.0% | -3.1pp |
| FY2022 | 2022-12-31 | 19.2% | -2.2pp |
| FY2021 | 2021-12-31 | 21.4% | — |
Operating Margin vs competitors
How ABT compares with its peers on the latest reported figures
- ABT's LTM Sep 2026 operating margin of 15.2% is the 8th highest of the 10 companies compared; the peer median is 20.4%.
- Its year-over-year change of -2.5 pp is the lowest of 10, against a peer median of -0.0 pp.
- Over three fiscal years its change of -1.0 pp compares with a peer median of -0.4 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Jun 2026 | 28.1% | +1.9 pp | -4.7 pp | |
| LTM Sep 2026 | 25.7% | -0.4 pp | +0.9 pp | |
| LTM Jun 2026 | 22.0% | +0.3 pp | -0.8 pp | |
| LTM Jun 2026 | 21.5% | +5.4 pp | +5.4 pp | |
| LTM Sep 2026 | 20.4% | -1.7 pp | -7.4 pp | |
| LTM Jul 2026 | 18.1% | +0.2 pp | +0.2 pp | |
| LTM Sep 2026 | 18.0% | -0.5 pp | -0.8 pp | |
| LTM Sep 2026 | 15.2% | -2.5 pp | -1.0 pp | |
| LTM Jun 2026 | 12.7% | -1.1 pp | -0.4 pp | |
| LTM Sep 2026 | 11.8% | -0.0 pp | +0.7 pp | |
| Peer median (excluding ABT) | 20.4% | -0.0 pp | -0.4 pp | |
Competitors are the stored peer set for ABT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 43.08B | 43.65B | 40.11B | 41.95B | 44.33B |
| Cost of Revenue | 19.86B | 21.33B | 20.07B | 20.63B | 19.72B |
| Gross Profit | 23.21B | 22.32B | 20.04B | 21.33B | 24.61B |
| Gross Margin | 53.9% | 51.1% | 50.0% | 50.8% | 55.5% |
| Research & Development | 2.74B | 2.85B | 2.72B | 2.82B | 2.96B |
| Selling, General & Admin | 11.28B | 11.11B | 10.88B | 11.65B | 12.38B |
| Operating Expenses | 14.01B | 13.96B | 13.6B | 14.47B | 16.59B |
| Depreciation & Amortization | 3.54B | 3.27B | 3.24B | 3.22B | 3.12B |
| EBITDA | 12.16B | 11.89B | 10.61B | 10.83B | 11.92B |
| EBITDA Margin | 28.2% | 27.2% | 26.4% | 25.8% | 26.9% |
| Operating Income | 9.2B | 8.36B | 6.44B | 6.83B | 8.05B |
| Operating Margin | 21.4% | 19.2% | 16.0% | 16.3% | 18.2% |
| Interest Income | 43M | 183M | 385M | 344M | 230M |
| Interest Expense | 410M | 315M | 698M | 603M | 341M |
| Other Income / Expenses | (989M) | (56M) | 229M | 188M | 418M |
| Income Before Tax | 8.21B | 8.31B | 6.66B | 7.01B | 8.47B |
| Pre-Tax Margin | 19.1% | 19.0% | 16.6% | 16.7% | 19.1% |
| Income Tax Expense | 1.14B | 1.37B | 941M | (6.39B) | 1.94B |
| Net Income | 7.07B | 6.93B | 5.72B | 13.4B | 6.52B |
| Net Margin | 16.4% | 15.9% | 14.3% | 31.9% | 14.7% |
| EPS (Basic) | 3.97 | 3.94 | 3.30 | 7.67 | 3.74 |
| EPS (Diluted) | 3.94 | 3.91 | 3.27 | 7.64 | 3.72 |
| Weighted Avg Shares | 1.78B | 1.75B | 1.73B | 1.73B | 1.75B |
| Weighted Avg Shares (Diluted) | 1.79B | 1.76B | 1.75B | 1.75B | 1.75B |
Abbott Laboratories
NYSE:ABT
Intrinsic Alpha fair value
Locked
Current Price
$104.48
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.